{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2009"],"condition":["Metastatic Colorectal Cancer","Colon Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colon Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2070218"],"location":["United States"],"study_start_month":["5"],"keyword":["CRC","Apo2L/TRAIL","Avastin","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer","description":"This is a multicenter, open-label study enrolling a total of up to 23 patients.","dates":{"creation":"2009-05-15"},"accession":"2070218","cross_references":{"ClinicalTrials___gov":["NCT00873756"]}}